BLL Stock Recent News

BALL's Q1 results reflect gains from higher volumes and price/mix across all segments.

Ball Corporation (NYSE:BALL ) Q1 2025 Earnings Conference Call May 6, 2025 11:00 AM ET Company Participants Brandon Potthoff - Director of Investor Relations Dan Fisher - Chief Executive Officer Howard Yu - Chief Financial Officer & Executive Vice President Conference Call Participants Ghansham Panjabi – Baird Stefan Diaz - Morgan Stanley Anthony Pettinari - Citi Phil Ng - Jefferies Edlain Rodriguez – Mizuho Josh Spector - UBS George Staphos - Bank of America Jeffrey Zekauskas - J.P. Morgan Michael Roxland - Truist Chris Parkinson - Wolfe Research Arun Viswanathan - RBC Operator Greetings, and welcome to the Ball Corporation First Quarter 2025 Earnings Conference Call.

Although the revenue and EPS for Ball (BALL) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Ball (BALL) came out with quarterly earnings of $0.76 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.68 per share a year ago.

Highlights First quarter U.S. GAAP total diluted earnings per share of 63 cents vs. $11.61 in 2024 First quarter comparable diluted earnings per share of 76 cents vs.

BALL's Q1 results are likely to reflect the impacts of the recent decline in customer demand, partially offset by positive pricing.

Get a deeper insight into the potential performance of Ball (BALL) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Ball (BALL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ball Corporation's anticipated EBITDA for 2025 is $1.98B, with a projected EPS of around $3.15 in my rather conservative scenario. Upside surprises are very possible. The company's net free cash flow is expected to increase due to reduced capex and lower interest expenses from debt reduction. Ball's 2030 and 2031 bonds offer a yield to maturity over 5.5%, presenting an attractive risk/reward profile for fixed income investors.

Vancouver, Canada, April 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce its upcoming live webinar titled "Gazing Through the Crystal Ball." The event is scheduled for May 21, 2025, at 12:00 PM ET (9:00 AM PT) and will feature a distinguished panel of experts discussing the evolving landscape of psychedelic science and business in the context of changing FDA policies and political climates.